National Cancer Institute (NCI) researchers recently reported complete and durable regression of chemorefractory metastatic ERBB2-negative and ER-positive breast cancer in a woman who received an experimental immunotherapy. The case report, published recently in Nature Medicine, involved a 49-year-old patient whose late-stage cancer was progressing despite multiple lines of chemotherapy and hormone treatments.
Abbasi J. Immunotherapy Leads to Complete Regression in Late-Stage Breast Cancer. JAMA. 2018;320(2):127. doi:10.1001/jama.2018.9486
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: